PURPOSE: To examine the risk of thromboembolic cardiovascular events in users of coxibs and NSAIDs in a nationwide cohort. METHODS: Data were synchronised from three nationwide databases, the Icelandic Medicines Registry (IMR), The Icelandic National Patient Registry (INPR) and the Registry for Causes of Death at Statistics Iceland (RCD), for prescriptions for NSAIDs or coxibs with respect to hospitalisation for unstable angina pectoris, myocardial infarction and cerebral infarction over a 3-year period. The Cox proportional hazards model and Poisson regression were used to analyse the data. RESULTS: A total of 108,700 individuals received prescriptions for NSAIDs or coxibs (ATC code M01A), of whom 78,539 received one drug only (163,406 person-years). Among those receiving only one drug 426 individuals were discharged from hospital with endpoint diagnoses. In comparison to diclofenac, the incidence ratios, adjusted for age and gender, were significantly higher for cerebral infarction (2.13; 95% CI 1.54-2.97; P < 0.001), for myocardial infarction (1.77; 95% CI 1.34-2.32; P < 0.001) and for unstable angina pectoris (1.52; 95% CI 1.01-2.30; P = 0.047) for patients who used rofecoxib. For naproxen users, the incidence ratio was 1.46 for myocardial infarction (95% CI 1.03-2.07; P = 0.03), but was reduced in ibuprofen users (0.63; 95% CI 0.40-1.00; P = 0.05). The youngest users of rofecoxib (< or =39 years) had the highest hazard ratio (HR) for cardiovascular events (8.34; P < 0.001), while those > or =60 years had a lower but still significantly elevated HR (1.35; P = 0.001). CONCLUSION: This Icelandic nationwide registry-based study amounting to 163,406 patient-years showed increased risk of cardiovascular events, i.e. cerebral infarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users. The added risk was most pronounced in young adults using rofecoxib.
PURPOSE: To examine the risk of thromboembolic cardiovascular events in users of coxibs and NSAIDs in a nationwide cohort. METHODS: Data were synchronised from three nationwide databases, the Icelandic Medicines Registry (IMR), The Icelandic National Patient Registry (INPR) and the Registry for Causes of Death at Statistics Iceland (RCD), for prescriptions for NSAIDs or coxibs with respect to hospitalisation for unstable angina pectoris, myocardial infarction and cerebral infarction over a 3-year period. The Cox proportional hazards model and Poisson regression were used to analyse the data. RESULTS: A total of 108,700 individuals received prescriptions for NSAIDs or coxibs (ATC code M01A), of whom 78,539 received one drug only (163,406 person-years). Among those receiving only one drug 426 individuals were discharged from hospital with endpoint diagnoses. In comparison to diclofenac, the incidence ratios, adjusted for age and gender, were significantly higher for cerebral infarction (2.13; 95% CI 1.54-2.97; P < 0.001), for myocardial infarction (1.77; 95% CI 1.34-2.32; P < 0.001) and for unstable angina pectoris (1.52; 95% CI 1.01-2.30; P = 0.047) for patients who used rofecoxib. For naproxen users, the incidence ratio was 1.46 for myocardial infarction (95% CI 1.03-2.07; P = 0.03), but was reduced in ibuprofen users (0.63; 95% CI 0.40-1.00; P = 0.05). The youngest users of rofecoxib (< or =39 years) had the highest hazard ratio (HR) for cardiovascular events (8.34; P < 0.001), while those > or =60 years had a lower but still significantly elevated HR (1.35; P = 0.001). CONCLUSION: This Icelandic nationwide registry-based study amounting to 163,406 patient-years showed increased risk of cardiovascular events, i.e. cerebral infarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users. The added risk was most pronounced in young adults using rofecoxib.
Authors: Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger Journal: Lancet Date: 2004 Dec 4-10 Impact factor: 79.321
Authors: E L Fosbøl; G H Gislason; S Jacobsen; F Folke; M L Hansen; T K Schramm; R Sørensen; J N Rasmussen; S S Andersen; S Z Abildstrom; J Traerup; H E Poulsen; S Rasmussen; L Køber; C Torp-Pedersen Journal: Clin Pharmacol Ther Date: 2008-11-05 Impact factor: 6.875
Authors: John A Baron; Robert S Sandler; Robert S Bresalier; Angel Lanas; Dion G Morton; Robert Riddell; Erik R Iverson; David L Demets Journal: Lancet Date: 2008-10-14 Impact factor: 79.321
Authors: Mendel D M Haag; Michiel J Bos; Albert Hofman; Peter J Koudstaal; Monique M B Breteler; Bruno H C Stricker Journal: Arch Intern Med Date: 2008-06-09
Authors: Peter Klimek; Dejan Baltic; Martin Brunner; Alexander Degelsegger-Marquez; Gerhard Garhöfer; Ghazaleh Gouya-Lechner; Arnold Herzog; Bernd Jilma; Stefan Kähler; Veronika Mikl; Bernhard Mraz; Herwig Ostermann; Claas Röhl; Robert Scharinger; Tanja Stamm; Michael Strassnig; Christa Wirthumer-Hoche; Johannes Pleiner-Duxneuner Journal: JMIR Med Inform Date: 2022-06-17
Authors: Mohammad Bakhriansyah; Patrick C Souverein; Anthonius de Boer; Olaf H Klungel Journal: J Clin Pharm Ther Date: 2019-04-07 Impact factor: 2.512
Authors: Ashleigh Hooimeyer; Alice Bhasale; Lucy Perry; Alice Fabbri; Annim Mohammad; Eliza McEwin; Barbara Mintzes Journal: Pharmacol Res Perspect Date: 2020-12
Authors: Georgios Athanasiadis; Joeri J Meijsen; Dorte Helenius; Andrew J Schork; Andrés Ingason; Wesley K Thompson; Daniel H Geschwind; Thomas Werge; Alfonso Buil Journal: Proc Natl Acad Sci U S A Date: 2022-02-08 Impact factor: 11.205
Authors: Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2015-11-17 Impact factor: 4.790
Authors: Grzegorz Grześk; Katarzyna Szadujkis-Szadurska; Grzegorz Matusiak; Bartosz Malinowski; Marta Gajdus; Michał Wiciński; Leszek Szadujkis-Szadurski Journal: Biomed Rep Date: 2014-01-29